Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination

Blow For Company’s HIV Strategy

 
• By Andrew McConaghie

Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.

Merck
Merck's goal of competing in a new generation of longer-acting HIV therapies could be hit by the safety setback. • Source: Alamy

More from Clinical Trials

More from R&D